The University of Pittsburgh and University of Pittsburgh Cancer Institute propose to conduct a Specialized Program of Research Excellence (SPORE) in Skin Cancer. The overall goals of the University Pittsburgh Skin Cancer SPORE are to improve the detection and treatment of skin cancer. The SPORE program will consist of six translational research projects in skin cancer, four cores including an administrative core, a developmental research program and a career development program. The University of Pittsburgh Skin Cancer SPORE will use an interdisciplinary approach to meet its objectives by carrying out projects with co- investigators in basic, applied and clinical science. It is also organ-specific in that its approach and all projects will test hypotheses about skin cancer biology, susceptibility, detection, or treatment. The long-term translational research projects that will serve as the basis for improving the outcome of patients diagnosed with skin cancer. The six main projects include: (1) Chemoprevention of Melanoma with Sulforaphane;(2) Multiple Antigen-Engineered DC Immunization and IFN? Boost for Metastatic Melanoma;(3) Polarized Dendritic Cells Guide Melanoma-Specific Responses;(4) Therapeutic Immune Targeting of EphA2 Expressed by Melanoma and Its Tumor-Associated Vasculature;(5) Delineating the DNA Repair pathways impacting alkylating agent efficacy in the treatment of Melanoma;(6) Augmentation of Dendritic Cell-based Immunotherapy for Sezary Syndrome by T-regs depletion. The four research cores will interact closely to assist the main research projects, developmental research projects and the career development investigators in carrying out translational skin cancer research. The research cores are: Core A. Administrative Core;Core B. Tissue Core;Core C. Immunological Monitoring and Cellular Products Laboratory (IMCPL);Core D. Biostatics. The Administrative Core will solicit feedback from the Internal and External Scientific Advisory Boards and provide scientific, regulatory and fiscal oversight for the SPORE program. The Skin SPORE investigators will work together to synergistically achieve the goals of the program and will also interact with investigators from SPOREs at other institutions to improve the outcome of patients with skin cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121973-05
Application #
8329701
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (O1))
Program Officer
Agarwal, Rajeev K
Project Start
2008-08-26
Project End
2013-07-31
Budget Start
2012-09-10
Budget End
2013-07-31
Support Year
5
Fiscal Year
2012
Total Cost
$2,300,000
Indirect Cost
$851,827
Name
University of Pittsburgh
Department
Dermatology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Retseck, Janet; VanderWeele, Robert; Lin, Hui-Min et al. (2016) Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immunother Cancer 4:38
Scharping, Nicole E; Menk, Ashley V; Moreci, Rebecca S et al. (2016) The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity 45:374-88
Villalona-Calero, Miguel A; Duan, Wenrui; Zhao, Weiqiang et al. (2016) Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 108:
Bengsch, Bertram; Johnson, Andy L; Kurachi, Makoto et al. (2016) Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity 45:358-73
Sottile, Rosa; Pangigadde, Pradeepa N; Tan, Thomas et al. (2016) HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol 46:409-19
Fan, Yiping; Lee, Seungjae; Wu, Gang et al. (2016) Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol 136:339-42
Davar, Diwakar; Kirkwood, John M (2016) Adjuvant Therapy of Melanoma. Cancer Treat Res 167:181-208
Butterfield, Lisa H (2016) Lessons learned from cancer vaccine trials and target antigen choice. Cancer Immunol Immunother 65:805-12
Zarour, Hassane M (2016) Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res 22:1856-64
Blackler, Ryan J; Evans, Dylan W; Smith, David F et al. (2016) Single-chain antibody-fragment M6P-1 possesses a mannose 6-phosphate monosaccharide-specific binding pocket that distinguishes N-glycan phosphorylation in a branch-specific manner†. Glycobiology 26:181-92

Showing the most recent 10 out of 162 publications